{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-073587","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.461480+00:00","generated_at":"2026-06-07T06:21:34.366174+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clearside Biomedical waives $12.5M milestone payment, releases escrow to HCR","bullets":["Subsidiary Clearside Royalty waived all rights to $12.5M milestone payment tied to XIPERE sales.","Payment held in escrow under 2022 Purchase Agreement; released to Healthcare Royalty Partners IV.","First Milestone Event required milestone by March 31, 2024; waiver eliminates potential payment.","Escrow agreement terminated upon release of funds to purchaser."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-073587","json":"https://secwatch.observer/filing/0000950170-23-073587.json","markdown":"https://secwatch.observer/filing/0000950170-23-073587.md","text":"https://secwatch.observer/filing/0000950170-23-073587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023073587/0000950170-23-073587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023073587/clsd-20231222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:21:34.366174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e550d926d574b89f880183a22ee92ed0a3036d52","claim":"Clearside Biomedical, Inc. amended Letter Agreement with Healthcare Royalty Partners IV, L.P., HCR Clearside SPV, LLC valued at $12.5 million milestone payment (effective 2023-12-22).","evidence_excerpt":"On December 22, 2023, Clearside Biomedical, Inc., through its wholly owned subsidiary Clearside Royalty LLC (\" Royalty Sub \"), entered into a letter agreement (the \" Letter Agreement \") with Healthcare Royalty Partners IV, L.P. (\" HCR \") and HCR Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC) (\" Agent \") amending that certain Purchase and Sale Agreement, dated as of August 8, 2022 (the \" Purchase Agreement \"), by and among Royalty Sub, HCR and Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023073587/0000950170-23-073587-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Healthcare Royalty Partners IV, L.P., HCR Clearside SPV, LLC"},{"label":"Value","value":"$12.5 million milestone payment"},{"label":"Effective","value":"2023-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}